Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma

María Luisa Palacios‐Berraquero, Paula Rodríguez-Márquez, María Eréndira Calleja-Cervantes, Nerea Berastegi, Aintzane Zabaleta, Leire Burgos, Diego Alignani, Patxi San Martín‐Úriz, Amaia Vilas‐Zornoza, Saray Rodríguez-Diaz, Susana Inogés, Ascensión López-Dı́az de Cerio, Sofía Huerga, Esteban Tamariz, J. Rifón, Ana Alfonso Piérola, Juan José Lasarte, Bruno Paiva, Mikel Hernáez, Paula Rodríguez‐Otero, Jesús F. San Miguel, Teresa Ezponda, Juan R. Rodríguez-Madoz, Felipe Prósper

This study investigates why patients receiving BCMA-directed CAR-T cell therapy for Multiple Myeloma often suffer from severe, long-lasting drops in blood cell counts (cytopenia). By combining clinical data with single-cell transcriptomics and ex-vivo models, the researchers discovered that activated CAR-T cells release inflammatory factors that "freeze" blood stem cells in an immature state, preventing them from developing into functional red and white blood cells.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of relapsed/refractory Multiple Myeloma (MM). However, a major "sting in the tail" is hematological toxicity. While acute side effects like Cytokine Release Syndrome (CRS) are now well-managed, many patients experience severe cytopenia (low neutrophils, platelets, and hemoglobin) that persists for months or even a year after treatment.

Historically, this was often attributed to the "bridge" chemotherapy used before CAR-T infusion. However, the persistence of these toxicities suggests a more complex biological mechanism. This paper seeks to move beyond clinical observation to identify the molecular "brakes" that CAR-T activation applies to the bone marrow's blood-production machinery.

Methods

The researchers employed a two-pronged approach:

  1. Clinical Correlation: They retrospectively analyzed a cohort of 48 MM patients to identify clinical biomarkers (like ferritin levels and baseline blood counts) that predict long-term toxicity.
  2. Ex-Vivo Modeling: To find the mechanism, they used a "paracrine" model. They took Hematopoietic Stem and Progenitor Cells (HSPCs) from healthy donors and cultured them in the presence of supernatants (the liquid "leftovers") from activated BCMA CAR-T cells.
  3. High-Resolution Analysis: They used flow cytometry to track cell surface markers and single-cell RNA sequencing (scRNA-seq) to map the transcriptional changes in over 14,000 cells. They also applied Gene Regulatory Network (GRN) analysis (using the SimiC algorithm) to identify the specific "master switches" (transcription factors) being flipped.

Datasets

  • Clinical Metadata: De-identified data from 48 adult patients with R/R MM treated at the University of Navarra.
  • scRNA-seq Data: A newly generated dataset of 14,248 cells (integrated from spCAR and control conditions), deposited in the GEO database under accession GSE250444.

Key Insights and Ideas

  • The "Maturation Arrest" Hypothesis: The most striking finding is that CAR-T cells don't necessarily kill blood stem cells. Instead, the inflammatory environment they create induces a state of "arrest." The stem cells stay alive but lose the ability to differentiate into mature, functional blood cells.
  • Paracrine Signaling is Sufficient: HSPCs do not express the BCMA antigen, meaning CAR-T cells aren't attacking them directly. The damage is "collateral," caused entirely by secreted factors (cytokines like IFNγ, TNFα, and IL-6) in the bone marrow niche.
  • Transcriptional Rewiring: The study identified a specific molecular signature of this arrest. In the presence of CAR-T "exhaust," cells upregulated transcription factors associated with early, undifferentiated states (GATA2, RUNX1, CEBPA) while failing to activate the "regulons" required for terminal maturation (ID2 for neutrophils and MAFB for monocytes).
  • Inflammation as a Predictor: High peak levels of ferritin (a marker of systemic inflammation) during the first days of treatment were strongly correlated with cytopenia lasting up to six months, suggesting that the intensity of the initial "cytokine storm" sets the stage for long-term marrow failure.

Key Results

  • High Incidence: 95.7% of patients experienced some form of cytopenia. Severe (Grade >3) neutropenia and thrombocytopenia were present in over 50% of patients one month after infusion.
  • Delayed Recovery: For many, recovery was slow; median time to platelet recovery was 90 days.
  • Phenotypic Halt: In ex-vivo cultures, supernatants from activated CAR-T cells significantly reduced the proportion of mature neutrophilic (CD10+CD16+), monocytic (CD14+CD35+), and erythroid (CD71+CD36+) cells compared to controls.
  • Molecular Signature: scRNA-seq confirmed that cells exposed to the CAR-T environment were enriched in pathways related to apoptosis and cell cycle arrest, while lacking the signatures of mature granulocytes and macrophages.

Limitations and Future Work

The authors acknowledge that while they have identified the effect of the inflammatory soup, they haven't yet pinpointed the exact combination of cytokines responsible for the maturation arrest. While IL-6 is a prime suspect, the use of the IL-6 blocker tocilizumab did not prevent cytopenia in their cohort, suggesting other factors (like IFNγ or TNFα) may be equally critical.

Future research is needed to determine if early intervention with a broader range of anti-inflammatory agents (e.g., anakinra or steroids) could protect the bone marrow niche without compromising the CAR-T cells' ability to kill the cancer. Additionally, validating these findings in larger, multi-center cohorts will be essential for developing standardized predictive models for patient risk.

Summary updated

Abstract

ABSTRACT Hematological toxicity is a common side effect of CAR-T therapies, being particularly severe in relapsed/refractory multiple myeloma (MM) patients. In this study, we analyzed a cohort of 48 patients treated with BCMA CAR-T cells to characterize the kinetics of cytopenia, identify predictive factors and determine potential mechanism underlying these toxicities. The overall incidence of cytopenia was 95.74%, and grade>3 thrombocytopenia and neutropenia one month after infusion was observed in 57% and 53% of the patients and was still present after 1 year in 4 and 3 patients respectively. Presence of cytopenia at baseline and high peak inflammatory markers highly correlated with cytopenia persisting up to three months. To determine potential mechanisms underpinning cytopenias, we evaluated the paracrine effect of BCMA CAR-T cells on the differentiation of HSPCs using an ex-vivo myeloid differentiation model. Phenotypic analysis showed that supernatants from activated CAR-T cells (spCAR) halted HSPCs differentiation promoting more immature phenotypes, with reduced expression of granulocytic, monocytic and erythroid markers. Single-cell RNAseq demonstrated an upregulation of transcription factors associated with early stages of hematopoietic differentiation in the presence of spCAR ( GATA2, RUNX1 and CEBPA) and decreased activity of key regulons involved in neutrophil and monocytic maturation ( ID2 and MAFB) . Our results suggest that CAR-T cell activation negatively influences hematopoietic differentiation through paracrine effects inducing arrest of HSPCs maturation and contributes to the understanding of severe cytopenia observed after CAR-T cell treatment in MM patients. These results may identify regulatory mechanisms involved in alter hematopoiesis and could lead to alternative therapeutic strategies. KEY POINTS Long-lasting cytopenia after BCMA CAR-T therapy correlates with baseline cytopenia and peak inflammatory markers. Supernatants from activated BCMA CAR-T cells induced an inhibition of ex-vivo myeloid differentiation and rewiring of transcriptional programs associated with hematopoietic differentiation.
BibTeX
@inproceedings{palaciosberraquero2024molecular,
  author = {María Luisa Palacios‐Berraquero and Paula Rodríguez-Márquez and María Eréndira Calleja-Cervantes and Nerea Berastegi and Aintzane Zabaleta and Leire Burgos and Diego Alignani and Patxi San Martín‐Úriz and Amaia Vilas‐Zornoza and Saray Rodríguez-Diaz and Susana Inogés and Ascensión López-Dı́az de Cerio and Sofía Huerga and Esteban Tamariz and J. Rifón and Ana Alfonso Piérola and Juan José Lasarte and Bruno Paiva and Mikel Hernáez and Paula Rodríguez‐Otero and Jesús F. San Miguel and Teresa Ezponda and Juan R. Rodríguez-Madoz and Felipe Prósper and Juan Roberto Rodriguez-Madoz and Felipe Prosper},
  title = {{Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma}},
  booktitle = {Blood},
  year = {2024},
  doi = {10.1182/bloodadvances.2023012522},
}
Figure